New York, USA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Market to Grow Substantially by 2032, Assesses DelveInsight | Key Companies - Melinta, AbbVie, Basilea, Motif Bio, Cubist, Paratek, Durata, The Medicine Company
The ABSSSI market is predicted to surge in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the estimated launch of emerging therapies.
DelveInsight’s Acute Bacterial Skin and Skin Structure Infections Market Insights report includes a comprehensive understanding of current treatment practices, ABSSSI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Acute Bacterial Skin and Skin Structure Infections Market Report
- As per DelveInsight’s analysis, the ABSSSI market is anticipated to grow at a significant CAGR by 2032.
- As per the DelveInsight estimates, the incidence of ABSSSI Infection is higher in men than women.
- Leading ABSSSI companies such as Melinta Therapeutics, Inc., AbbVie, Basilea Pharmaceutica, Motif Bio, Cubist Pharmaceutical, Paratek Pharmaceutical, Menarini Group, Durata Therapeutics, The Medicine Company, Weyth Pharmaceutical, Cubist Pharmaceutical, Pfizer, Allergan Plc, and others are currently working in the ABSSSI market.
- Some of the key therapies for ABSSSI treatment include Oritavancin, Dalbavancin, Ceftobiprole medocaril, Iclaprim, Sivextro, Nuzyra, Baxdela (Delafloxacin/Quofenix), Dalbavancin, Orbactiv (Oritavancin), Tygacil (Tigecycline), Cubicin (Daptomycin), Zyvox, Teflaro (ceftaroline fosamil), and others.
Discover which therapies are expected to grab the major ABSSSI market share @ Acute Bacterial Skin and Skin Structure Infections Market Report
Acute Bacterial Skin and Skin Structure Infections Overview
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) encompass a range of bacterial infections that affect the skin and underlying tissue. These infections can lead to discomfort, pain, and potentially severe complications if not promptly diagnosed and treated. The primary causative agents of ABSSSI are various strains of bacteria, most commonly Staphylococcus aureus and Streptococcus pyogenes, though other bacterial species can also be involved.
Symptoms of ABSSSI can vary but often include localized redness, swelling, warmth, and tenderness at the injection site. In more severe cases, patients may experience fever, chills, and the development of pus-filled abscesses. These infections can arise from a variety of sources, including minor cuts, wounds, surgical incisions, and even insect bites. Risk factors such as weakened immune systems, chronic medical conditions, and poor hygiene practices can also increase susceptibility to ABSSSI.
Diagnosing ABSSSI typically involves a clinical assessment by a healthcare provider, who will examine the affected area, assess symptoms, and consider the patient’s medical history. Laboratory tests, such as blood cultures and wound swabs, may be conducted to identify the specific bacteria causing the infection. In some cases, imaging studies like ultrasound or MRI might be used to evaluate the extent of tissue involvement.
Acute Bacterial Skin and Skin Structure Infections Epidemiology Segmentation
The ABSSSI epidemiology section provides insights into the historical and current ABSSSI patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The ABSSSI market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incidence Cases of ABSSSI Community/Hospital Settings
- Age-related Cases of ABSSSI
- Gender-specific Incident Cases of ABSSSI
Download the report to understand which factors are driving ABSSSI epidemiology trends @ ABSSSI Epidemiological Insights
Acute Bacterial Skin and Skin Structure Infections Treatment Market
The ABSSSI treatment is a comprehensive approach that encompasses various medical interventions to effectively combat the infection and promote healing. Antibiotics remain a fundamental component of ABSSSI treatment, selected based on factors like the type of bacteria identified, local antibiotic resistance patterns, and the patient's health status. Empirical antibiotic therapy is often initiated while awaiting laboratory results, and adjustments are made accordingly. In severe cases, hospitalization might be necessary, allowing for intravenous antibiotics to be administered under close medical supervision. As the infection responds to treatment, a shift from intravenous to oral antibiotics may be considered, promoting a smoother transition to outpatient care.
Beyond antibiotic therapy, meticulous wound care and hygiene are paramount. Cleaning the affected area, removing necrotic tissue, and applying sterile dressings facilitate the healing process and reduce the risk of further complications. Pain management strategies, ranging from over-the-counter analgesics to prescription pain relievers, contribute to the patient's comfort and overall recovery. In some instances, surgical intervention may be required to drain abscesses or remove infected tissue. This approach can accelerate healing and prevent the infection from spreading to deeper layers of skin or surrounding tissues.
Patient education and adherence to the prescribed treatment plan play a crucial role in ABSSSI management. Patients are advised to complete the full course of antibiotics, even if symptoms improve, to ensure the eradication of the infection and minimize the risk of recurrence or antibiotic resistance. Regular follow-up appointments allow healthcare providers to monitor progress, assess the effectiveness of treatment, and make any necessary adjustments. Collaborative decision-making between the medical team and the patient is key to tailoring treatment to individual needs and ensuring the best possible outcome in cases of ABSSSI.
To know more about ABSSSI treatment, visit @ ABSSSI Treatment Drugs
Key Acute Bacterial Skin and Skin Structure Infections Therapies and Companies
- Oritavancin: Melinta Therapeutics, Inc.
- Dalbavancin: AbbVie
- Ceftobiprole medocaril: Basilea Pharmaceutica
- Iclaprim: Motif Bio
- Sivextro: Cubist Pharmaceutical
- Nuzyra: Paratek Pharmaceutical
- Baxdela (Delafloxacin/Quofenix): Menarini Group/Melinta Therapeutics
- Dalbavancin: Durata Therapeutics
- Orbactiv (Oritavancin): The Medicine Company
- Tygacil (Tigecycline): Weyth Pharmaceutical
- Cubicin (Daptomycin): Cubist Pharmaceutical
- Zyvox: Pfizer
- Teflaro (ceftaroline fosamil): Allergan Plc
Learn more about the FDA-approved drugs for ABSSSI @ Drugs for Acute Bacterial Skin and Skin Structure Infections Treatment
Acute Bacterial Skin and Skin Structure Infections Market Dynamics
The ABSSSI market dynamics are influenced not only by scientific and regulatory factors but also by shifting demographics and healthcare trends. The aging population, increased prevalence of chronic conditions like diabetes, and a rise in invasive medical procedures contribute to a higher susceptibility to skin infections, thus driving the demand for effective ABSSSI treatments.
The ABSSSI market is characterized by a continuous pursuit of therapies that offer not only improved clinical outcomes but also convenience in administration, such as oral or outpatient treatments that can reduce the burden on healthcare facilities. This demand for patient-friendly options propels pharmaceutical companies to invest in research that focuses on targeted therapies, combination treatments, and innovative drug delivery methods.
Healthcare reimbursement policies and cost considerations also play a significant role in shaping the ABSSSI market. Striking a balance between making effective treatments accessible to patients and ensuring the financial sustainability of healthcare systems remains a challenge. As a result, pricing strategies and negotiation dynamics between pharmaceutical manufacturers and payers significantly impact market access and the adoption of new treatments.
Furthermore, the global interconnectedness of healthcare systems highlights the need for a coordinated effort to tackle ABSSSI. International organizations, governments, and healthcare bodies collaborate to establish guidelines for antibiotic use, infection prevention, and surveillance to curb the rise of antibiotic-resistant strains.
In this ever-evolving landscape, partnerships and collaborations between academia, pharmaceutical companies, and research institutions are fostering innovation. The exploration of precision medicine approaches, leveraging genomic data to tailor treatments, and harnessing advanced technologies like artificial intelligence for drug discovery further contribute to the dynamic ABSSSI market.
| Acute Bacterial Skin and Skin Structure Infections Report Metrics | Details |
| Study Period | 2019–2032 |
| Acute Bacterial Skin and Skin Structure Infections Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Acute Bacterial Skin and Skin Structure Infections Companies | Melinta Therapeutics, Inc., AbbVie, Basilea Pharmaceutica, Motif Bio, Cubist Pharmaceutical, Paratek Pharmaceutical, Menarini Group, The Medicine Company, Weyth Pharmaceutical, Cubist Pharmaceutical, Pfizer, Allergan Plc, and others |
| Key Acute Bacterial Skin and Skin Structure Infections Therapies | Oritavancin, Dalbavancin, Ceftobiprole medocaril, Iclaprim, Sivextro, Nuzyra, Baxdela (Delafloxacin/Quofenix), Dalbavancin, Orbactiv (Oritavancin), Tygacil (Tigecycline), Cubicin (Daptomycin), Zyvox, Teflaro (ceftaroline fosamil), and others |
Scope of the Acute Bacterial Skin and Skin Structure Infections Market Report
- Therapeutic Assessment: Acute Bacterial Skin and Skin Structure Infections current marketed and emerging therapies
- Acute Bacterial Skin and Skin Structure Infections Market Dynamics: Attribute Analysis of Emerging Acute Bacterial Skin and Skin Structure Infections Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Acute Bacterial Skin and Skin Structure Infections Market Access and Reimbursement
Discover more about ABSSSI drugs in development @ ABSSSI Clinical Trials
Table of Contents
| 1. | Acute Bacterial Skin and Skin Structure Infections Market Key Insights |
| 2. | Acute Bacterial Skin and Skin Structure Infections Market Report Introduction |
| 3. | Acute Bacterial Skin and Skin Structure Infections Market Overview at a Glance |
| 4. | Acute Bacterial Skin and Skin Structure Infections Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Acute Bacterial Skin and Skin Structure Infections Treatment and Management |
| 7. | Acute Bacterial Skin and Skin Structure Infections Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Acute Bacterial Skin and Skin Structure Infections Marketed Drugs |
| 10. | Acute Bacterial Skin and Skin Structure Infections Emerging Drugs |
| 11. | Seven Major Acute Bacterial Skin and Skin Structure Infections Market Analysis |
| 12. | Acute Bacterial Skin and Skin Structure Infections Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Acute Bacterial Skin and Skin Structure Infections Epidemiology
Acute Bacterial Skin and Skin Structure Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted ABSSSI epidemiology in the 7MM.
Acute Bacterial Skin and Skin Structure Infections Pipeline
Acute Bacterial Skin and Skin Structure Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ABSSSI companies including Nabriva Therapeutics, TenNor Therapeutics, Basilea Pharmaceutica, among others.
Group B Streptococcus Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key group B Streptococcus companies including Minervax ApS, Pfizer, among others.
Bacterial Skin Diseases Market
Bacterial Skin Diseases Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial skin diseases companies including Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., AbbVie Inc., among others.
Bacterial Skin Diseases Pipeline
Bacterial Skin Diseases Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bacterial skin diseases companies including Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., AbbVie Inc., among others.
Bacterial Skin Diseases Epidemiology
Bacterial Skin Diseases Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted bacterial skin diseases epidemiology in the 7MM.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
